MR1 and neoplasm: Therefore, an ideal strategy would involve developing ligand variants that target MAIT cell‐specific TCR signaling patterns or selectively enhancing MR1‐mediated presentation of tumor‐associated self‐antigens through metabolic intervention (e.g., modulation of the riboflavin metabolism pathway in tumor cells), thereby specifically activating antitumor responses [288, 290, 291].